Crémieux Profile picture
Feb 20 • 17 tweets • 6 min read • Read on X
The biggest news today should probably be about one of the Executive Orders from yesterday evening.

Trust me, it's big.

The President just authorized DOGE to start cutting regulationsđź§µ Image
This order starts off huge.

Remember those recently-created DOGE Team Leads going into every agency? They're going to work with agency heads and the OMB to review all of the regulations across a number of huge categories.

Which categories? Let's see.

Image
The first category is those rules and regulations which violate the law of the land: unlawful and unconstitutional regulations, things that agencies enacted but which they shouldn't have been able to. Image
Now you might ask: Who decides what's lawful or unlawful, constitutional or unconstitutional, a good or a bad interpretation of statutes, prohibitions, and the law writ large?

Try to keep up, because the administration outlined this a few days ago:
The next category of regulations that DOGE will be purging is sizable.

DOGE was tasked with purging the federal government of socially significant regulations that Congress didn't roll out, and regulations that are costly for private entities without benefitting the public more. Image
This next category of regulations is where things get huge.

DOGE will be purging all regulations that impede innovation and infrastructure, make it harder to response to natural and manmade disasters, and just generally anything unnecessarily standing in the way of business. Image
Now obviously this is a major task, but don't worry: the next section says which regulations to focus on first.

It says to focus on regulations that are particularly important. This is totally logical: get rid of the big barriers to growth first, and then move down the list. Image
The next section might be my favorite part of this whole Order.

This section calls for an end to bureaucratic overreach.

It says that if a bureaucrat is doing more than they're required to, they need to stop it. This means fewer bureaucrats abusing their 'authority'. Image
Additionally, if agencies are currently engaged in overreach in the enforcement of rules and regulations, they're going to stop.

This can also apply to rules and regulations that the President does not want enforced in a given way based on his valid interpretation of said rule. Image
And finally, the Order says what to do with new regulations:

Run them by DOGE, and if they're a barrier to business or a burden on the public, they won't go into effect.Image
Every new regulation will be reviewed and every existing regulation will be reviewed too, and all barriers to growth that can be extirpated from the Federal Register will be extirpated from it.

This authority is expansive and unprecedented, and the admin was building to this.
And just to be sure, there's still more to come.

DOGE is enabling the digitization of records, the installation of modern systems and tools that will enable the U.S. to be governed in a modern, rapid, and flexible way.

That's its purpose, is making a 21st-century government.
And why?

Well obviously because regulations are burdensome, the spending has been too high, and so on, but this Order contains another clue. Image
One of Trump's goals is ending the secret fourth branch of government that persists between Presidencies and ensures Democrats are always in power.

It is an explicit goal of this Administration to end the "Administrative State."
In their Fact Sheet on this Executive Order, the Presidency stated that it is their goal to end the extreme burdens on the American people from this unconstitutional fourth branch of government, and to stop them from prying into American lives forevermore. Image
It is hard to overstate how huge this Order is.

There are hundreds of thousands of federal regulations, and a very large portion of them can be stripped back with executive authority alone.

And now, DOGE has been enabled to start that process, with all that entails.
That entails a lot, but I'll cut myself off here. And keep in mind, this is just the first month of this administration.

Here's the Executive Order: whitehouse.gov/presidential-a…

Here's the Fact Sheet: whitehouse.gov/fact-sheets/20…

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Crémieux

Crémieux Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @cremieuxrecueil

Jun 16
Novo Nordisk failed to pay a small patent maintenance fee in Canada a few years ago.

As a result, a generic version of Ozempic will be available there soon.

The HHS can exploit this oversight to decisively end the chronic disease crisis, if it has the courageđź§µ Image
First, a bit of background.

Novo Nordisk is a pharmaceutical company that makes drugs for diabetes.

The blockbuster drug that turned them into a major pharma player is semaglutide, which they sell under the brand names Wegovy, Ozempic, and Rybelsus. Image
Semaglutide has been amazingly successful.

It greatly assists in the management of diabetes, and it causes major weight loss with minimal side effects for most.

Its utility for treating obesity is somewhere between an earlier daily version (liraglutide) and bariatric surgery. Image
Read 26 tweets
Jun 14
One of the reasons I'm bullish on Eli Lilly over Novo Nordisk is that I don't think Novo can hack it against a much more R&D-focused American company run by a shrewd corporate climber.

Novo seems like its leadership is much more naĂŻve. Image
Eli Lilly's investments just seem to be superior to Novo's, which have mostly been falling through recently.

The best Novo seems capable of doing now is mimicking Eli Lilly's next drug, retatrutide.

If they were smart, they would do some collaborations.

But I am a believer in something like a Great Man theory of business success.

There's lots of evidence for it. For example, when high-earning business owners die, the profits of their businesses drop right away.

Turns out, they were compensated for real value to the business. Image
Read 5 tweets
Jun 13
Companies are rapidly improving on GLP-1 weight loss.

Regeneron just paired semaglutide (Ozempic/Wegovy) with a myostatin inhibitor and the result was...

- More fat loss
- Less muscle loss Image
The problem is that adding things to GLP-1RA treatment might lead to more side effects and worse adherence as a result.

But that seems to not be a concern with a low-dose myostatin inhibitor: added side effects only become concerning with more advanced treatment. Image
The weight loss that comes with using GLP-1RAs is already similar to normal weight loss compositionally.

These new drugs thus present with an interesting prospect: that pharmacotherapy-driven weight loss will soon be superior to normal weight loss!Image
Read 8 tweets
Jun 4
This 91 vs 103 thing is either ignorance or chicanery.

The issue has been explained to him multiple times, but TL;DR:

(1) The standardized difference is still the same 1 SD its always been, (2) IQ does not have a ratio scale, (3) the population hasn't gotten smarter. Image
If you want to understand this error, I have material aplenty for you.

First, on the issue of rescaling differences, here's a post:
Second, on the issue of the scale of the gap, as of 2023, it had not shrunken from where it stood in World War I: cremieux.xyz/p/the-state-of…
Read 8 tweets
Jun 4
The Wall Street Journal just published the FDA's Opinion piece-length rationale for banning talc.

I was happy to see they were citing studies, but after I read the studies, I was dismayed:

The FDA fell victim to bad science, and they might ban talcum powder because of it!

đź§µ Image
The evidence cited in the article is

- A 2019 meta-analysis
- A review by the International Agency for Research on Cancer (IARC)
- A 2019 cohort study from Taiwan

Let's go through each of these and see if the FDA's evidence holds water. Image
The first piece of evidence they cite is a meta-analysis, and it's a doozy.

The study includes 27 estimates of the observational association between talc use and ovarian cancer rates.

Three estimates come from cohort studies. Those are fine. The problem is the 24 other studies.
Read 42 tweets
Jun 3
Let's make this even clearer.

The severity of COVID vaccine-related myocarditis was far lower than the severity of COVID-related myocarditis, which instead looked like regular viral myocarditis.

You can see this in many cohorts. For example, this was seen in France: Image
This result replicates everywhere it's tested.

We knew this from the initial small studies... Image
Image
And we knew this based on somewhat larger Scandinavian register-based work as well

Do note, however, that the Scandinavian work had a poor case definition for infection-driven myocarditis compared to other cohorts. As the long-term study linked in the QT shows, they missed most Image
Read 22 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Don't want to be a Premium member but still want to support us?

Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal

Or Donate anonymously using crypto!

Ethereum

0xfe58350B80634f60Fa6Dc149a72b4DFbc17D341E copy

Bitcoin

3ATGMxNzCUFzxpMCHL5sWSt4DVtS8UqXpi copy

Thank you for your support!

Follow Us!

:(